| Online-Ressource |
Verfasst von: | Rementer, Cameron [VerfasserIn]  |
| Yavirach, Apichai [VerfasserIn]  |
| Buranaphatthana, Worakanya [VerfasserIn]  |
| Walczak, Philip A. [VerfasserIn]  |
| Speer, Mei [VerfasserIn]  |
| Pierce, Kat [VerfasserIn]  |
| Dharmarajan, Subramanian [VerfasserIn]  |
| Leber, Elizabeth [VerfasserIn]  |
| Sangiorzan, Bruce [VerfasserIn]  |
| Bain, Steven [VerfasserIn]  |
| Scatena, Marta [VerfasserIn]  |
| Blümke, Alexander Felix [VerfasserIn]  |
| Giachelli, Cecilia M. [VerfasserIn]  |
Titel: | Engineered myeloid precursors differentiate into osteoclasts and resorb heterotopic ossification in mice |
Verf.angabe: | Cameron Rementer, Apichai Yavirach, Worakanya Buranaphatthana, Philip A. Walczak, Mei Speer, Kat Pierce, Subramanian Dharmarajan, Elizabeth Leber, Bruce Sangiorzan, Steven Bain, Marta Scatena, Alexander Blümke and Cecilia M. Giachelli |
E-Jahr: | 2024 |
Jahr: | 22 November 2024 |
Umfang: | 12 S. |
Fussnoten: | Gesehen am 16.04.2025 |
Titel Quelle: | Enthalten in: Frontiers in Bioengineering and Biotechnology |
Ort Quelle: | Lausanne : Frontiers Media, 2013 |
Jahr Quelle: | 2024 |
Band/Heft Quelle: | 12(2024), Seite 1-12 |
ISSN Quelle: | 2296-4185 |
Abstract: | Introduction - Heterotopic ossification (HO) occurs following orthopedic trauma, spinal cord injuries, brain trauma and limb amputations. Once symptomatic, HO causes pain, limited mobility and decreased quality of life. Current treatments are limited and have significant complications with high recurrence rates, underscoring the need for improved therapeutic interventions. Osteoclasts (OCs) are physiological bone resorptive cells that secrete enzymes and protons to degrade bone. - - Methods - In this study, we describe the use of genetically engineered OCs as a novel cell therapy approach to treat HO. Inducible, engineered myeloid precursors (iRANK cells) treated with a chemical inducer of dimerization (CID) differentiated into TRAP+ multinucleated OCs and resorbed mineralized tissues in vitro. - - Results - In vivo, BMP-2-induced murine HO lesions were significantly regressed following treatment using iRANK cells with concomitant systemic administration of CID. Moreover, many OCs were TRAP+, MMP9+, and GFP+, indicating that they differentiated from delivered iRANK cells. - - Discussion - In summary, these data con rm the ability of engineered myeloid precursors to differentiate into OCs and resorb HO in vivo paving the way for OC delivery as a promising approach for HO treatment. |
DOI: | doi:10.3389/fbioe.2024.1491962 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.3389/fbioe.2024.1491962 |
| Volltext: https://www.frontiersin.orghttps://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe. ... |
| DOI: https://doi.org/10.3389/fbioe.2024.1491962 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | Chemical inducer of dimerization |
| Engineered Osteoclasts |
| heterotopic ossification |
| Osteoclasts |
| Rank |
| Resorption |
K10plus-PPN: | 1923046055 |
Verknüpfungen: | → Zeitschrift |
Engineered myeloid precursors differentiate into osteoclasts and resorb heterotopic ossification in mice / Rementer, Cameron [VerfasserIn]; 22 November 2024 (Online-Ressource)